Forte Biosciences, Inc.
FBRXDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001419041
Forte Biosciences, Inc. was delisted in 2026; its insiders filed their last Form 4 on Aug 27, 2026; 86 institutions reported holding it in 13F filings for Q2 2026, worth $432.7M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 86
- Q2 2026, +19 vs. previous quarter
- 13F value
- $432.7M
- Reported value at the end of Q2 2026
- Superinvestors holding
- 0
- At the end of Q2 2026
Superinvestors holding FBRX, Q2 2026
No superinvestor reported holding FBRX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Forte Biosciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 2, 2026 (view filing) | Dec 30, 2025 | 3 days | Riley Antony ACHIEF FINANCIAL OFFICER | PPurchase | +9.68K | $26.33 | +$254.9K | +30.4%41.5K after | |
| Nov 22, 2024 (view filing) | Nov 21 | 1 day | Riley Antony ACHIEF FINANCIAL OFFICER | PPurchase | +22.5K | $5.55 | +$125.0K | +272.5%30.8K after | |
| Dec 20, 2023 (view filing) | Dec 18 | 2 days | Wagner Paul A.See Remarks | PPurchase | +10.0K | $0.75 | +$7.50K | +0.6%1.82M after | |
| Dec 15, 2023 (view filing) | Dec 13-14 | 2 days | Wagner Paul A.See Remarks | PPurchase | +20.5K | $0.7097 | +$14.6K | +1.1%1.81M after | 2 lots |
| Dec 12, 2023 (view filing) | Dec 11-12 | 1 day | Wagner Paul A.See Remarks | PPurchase | +29.8K | $0.65 | +$19.4K | +1.7%1.79M after | 2 lots |
| Dec 8, 2023 (view filing) | Dec 7-8 | 1 day | Wagner Paul A.See Remarks | PPurchase | +51.2K | $0.5917 | +$30.3K | +3.0%1.76M after | 2 lots |
| Nov 22, 2023 (view filing)5:51 PM ET | Nov 20-22 | 2 days | Wagner Paul A.See Remarks | PPurchase | +7.37K | $0.4371 | +$3.22K | +0.4%1.71M after | 4 lots |
| Dec 19, 2022 (view filing) | Dec 15-16 | 4 days | Wagner Paul A.See Remarks | PPurchase | +100.0K | $1.05 | +$104.8K | +7.8%1.38M after | 2 lots |
| Sep 8, 2021 (view filing) | Sep 7 | 1 day | Wagner Paul A.See Remarks | SSale | −1.00M | $4.35 | −$4.35M | −43.9%1.28M after | |
| Sep 7, 2021 (view filing) | Sep 7 | Same day | Riley Antony AChief Financial Officer | SSale | −25.0K | $4.24 | −$106.1K | −69.3%11.1K after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Forte Biosciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Federated Hermes, Inc. | 2,110,516 | $44.8M | 0.06% | +345,000+19.5% | Added |
| OrbiMed Advisors LLC | 1,577,705 | $33.5M | 0.64% | +380,750+31.8% | Added |
| Fred Alger Management, LLC | 1,439,697 | $30.6M | 0.10% | +165,732+13.0% | Added |
| Jupiter Topco LLC | 1,373,060 | $29.2M | 0.01% | +1,373,060 | New |
| BlackRock, Inc. | 1,222,862 | $26.0M | 0.00% | +1,156,941+1,755.0% | Added |
| Affinity Asset Advisors, LLC | 1,145,391 | $24.3M | 1.19% | +133,501+13.2% | Added |
| MPM Oncology Impact Management LP | 987,448 | $21.0M | 1.28% | −13,234−1.3% | Reduced |
| TCG Crossover Management, LLC | 920,000 | $19.6M | 0.47% | +920,000 | New |
| Vanguard Capital Management LLC | 861,737 | $18.3M | 0.00% | +330,045+62.1% | Added |
| Woodline Partners LP | 712,753 | $15.1M | 0.05% | +380,766+114.7% | Added |